Results 81 to 90 of about 4,717 (108)

Methenamin-3-chlorallylchlorid: MAK-Begründung, Nachtrag. [PDF]

MAK Collect Occup Health Saf
Hartwig A, MAK Commission https://www.dfg.de/de/ueber-uns/gremien/senat/arbeitsstoffe/mitglieder.   +1 more
europepmc   +1 more source

[Drug-drug interactions in critically ill patients]. [PDF]

Med Klin Intensivmed Notfmed
Bellmann R, Weiler S.
europepmc   +1 more source

Tetrahydrofuran: MAK-Begründung, Nachtrag. [PDF]

MAK Collect Occup Health Saf
Hartwig A, MAK Commission.
europepmc   +1 more source

[Long-term follow up of efficiency and safety of CD19-CAR T-cell treatment of systemic lupus erythematosus]. [PDF]

Z Rheumatol
Taubmann J, Böltz S, Hagen M, Wirsching A, Müller F, Völkl S, Kharboutli S, Spörl S, Garantziotis P, Aigner M, Grieshaber-Bouyer R, Mackensen A, Schett G.   +12 more
europepmc   +1 more source

Aluminiumverbindungen, lösliche: MAK-Begründung. [PDF]

MAK Collect Occup Health Saf
Hartwig A, MAK Commission https://www.dfg.de/de/ueber-uns/gremien/senat/arbeitsstoffe/mitglieder.   +1 more
europepmc   +1 more source

[Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases]. [PDF]

Strahlenther Onkol
Guhlich M, Rieken S.
europepmc   +1 more source

[Possible Gadolinium Deposition Disease - a case report]. [PDF]

Rofo
Diekhoff T, Böhmerle W, Habbel JP.
europepmc   +1 more source